Hyderabad-headquartered Gland Pharma on Tuesday said it had inked a pact with Russian Direct Investment Fund (RDIF) to supply 252 million doses of the Covid-19 vaccine Sputnik V. This is part of the Russian sovereign wealth fund’s efforts to increase manufacturing capacities in India to make for the country and to augment global supplies. Sources said Bengaluru-based Strides Pharma Science, too, is in fray for contract manufacturing the Sputnik V. Another Hyderabad-based player, Hetero, will supply 100 million doses of the vaccine. RDIF has lined up 250 million doses for India over the next 12 months, and the rest will be for global supplies.